US20030212379A1 - Systems and methods for remotely controlling medication infusion and analyte monitoring - Google Patents

Systems and methods for remotely controlling medication infusion and analyte monitoring Download PDF

Info

Publication number
US20030212379A1
US20030212379A1 US10/370,955 US37095503A US2003212379A1 US 20030212379 A1 US20030212379 A1 US 20030212379A1 US 37095503 A US37095503 A US 37095503A US 2003212379 A1 US2003212379 A1 US 2003212379A1
Authority
US
United States
Prior art keywords
medication
system
physiological fluid
patient
user
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/370,955
Inventor
Adam Bylund
William Durban
Michael Wardle
Karen Long
Joseph McCluskey
Ulrich Kraft
Manfred Ebner
Matthias Stiene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeScan Inc
Original Assignee
LifeScan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US36040102P priority Critical
Application filed by LifeScan Inc filed Critical LifeScan Inc
Priority to US10/370,955 priority patent/US20030212379A1/en
Assigned to LIFESCAN, INC. reassignment LIFESCAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EBNER, MANFRED, KRAFT, ULRICH, LONG, KAREN M., MCCLUSKY, JOE, STEINE, MATTHIAS, WARDLE, MICHAEL D., DURBAN, WILLIAM JEFFEREY, BYLUND, ADAM DAVID
Assigned to LIFESCAN, INC. reassignment LIFESCAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STIENE, MATTHIAS, BYLUND, ADAM DAVID, KRAFT, ULRICH, EBNER, MANFRED, LONG, KAREN M., DURBAN, WILLIAM JEFFEREY, MCCLUSKY, JOSEPH, WARDLE, MICHAEL D.
Publication of US20030212379A1 publication Critical patent/US20030212379A1/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4836Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/0002Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0015Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
    • A61B5/002Monitoring the patient using a local or closed circuit, e.g. in a room or building
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • A61B5/14514Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/74Details of notification to user or communication with user or patient ; user input means
    • A61B5/7475User input or interface means, e.g. keyboard, pointing device, joystick
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/3456Computer-assisted prescription or delivery of medication, e.g. prescription filling or compliance checking
    • G06F19/3468Computer-assisted delivery of medication via infusion or injection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/04Constructional details of apparatus
    • A61B2560/0406Constructional details of apparatus specially shaped apparatus housings
    • A61B2560/0412Low-profile patch shaped housings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0295Strip shaped analyte sensors for apparatus classified in A61B5/145 or A61B5/157
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M2005/1401Functional features
    • A61M2005/1405Patient controlled analgesia [PCA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M2005/14208Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/18General characteristics of the apparatus with alarm
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3576Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3576Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3592Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/20Blood composition characteristics
    • A61M2230/201Glucose concentration

Abstract

Devices, systems and methods are provided for remotely controlling medication delivery to a patient by means of a medication infusion pump, such as a subcutaneous infusion pump, and for remotely controlling the monitoring of one or more physiological fluid analytes such as by a percutaneous measurement device. The systems of the present invention include a medication infusion pump and a hand-held “fob” for the remote control of the infusion pump and/or measurement device. In addition to remotely controlling the insulin pump and the measurement device, the fob provides for the consolidation of blood chemistry data and insulin delivery data over a period of time and maintains such consolidated data for immediate and later retrieval by the user or a physician. The methods of the present invention allow a user to customize and optimize an insulin bolus delivery protocol, i.e., bolus volume and delivery duration, by factoring in or compensating for the user's current or substantially current blood chemistry evaluation and/or the user's anticipated and/or actual carbohydrate intake.

Description

    FIELD OF THE INVENTION
  • The invention generally relates to continuous-delivery medication infusion systems and physiological fluid characteristic monitoring systems. More particularly, the invention is related to the user-interactive remote control of such continuous-delivery medication infusion systems and physiological fluid characteristic monitoring systems, as well as the integration of such physiological fluid characteristic monitoring systems within a remote control device. [0001]
  • BACKGROUND OF THE INVENTION
  • Medication infusion devices and physiological fluid characteristic monitoring devices are known in the medical field. One very common application of such devices is the delivery of insulin to and the monitoring of blood glucose levels of diabetics. Many advances have been made in recent years, with such device being integrated together to provide an all-in-one device which provides for the controlled delivery of insulin to the patient in accordance with real-time patient blood glucose levels and other requirements. [0002]
  • One such device is disclosed in U.S. Pat. No. 5,665,065 which provides for an automatic infusion pump for the continuous, programmed delivery of insulin at a subcutaneous location within the patient. The pump is designed for the programmable delivery of insulin from a reservoir to the patient via tubing implanted within the patient according to a predefined protocol. The pump housing includes an integrated blood sensor for deriving a patient's current blood glucose level. In addition to the current blood chemistry data, the device is configured to receive data from the patient relating to event-specific patient activities, e.g., a variation in the patient's exercise or meal schedule or an increase or decrease in the anticipated intake of food, which are likely to affect the patient's current blood chemistry. Such event-specific data and blood characteristics are provided to a central controller/processor housed within the pump-monitor device which modifies the insulin delivery protocol automatically, making the necessary changes in the dosage of insulin and the timing of the delivery of such dosage by the pump. [0003]
  • While such highly automated devices have their advantages, many patients want more direct control over the administration of their medication. For example, a patient may want to stop the administration of medication during a dosage delivery period, even where the initial administration was initiated by the patient rather than according to a preprogrammed algorithm. Circumstances that may present such a situation include, for example, a change in the anticipated intake of carbohydrates by a diabetic, e.g., during a meal, a patient finds himself eating an amount of carbohydrates greater or less than what he or she anticipated prior to the meal. Such circumstances may require immediate modification of the then current insulin delivery parameters in effect on the pump. [0004]
  • Accordingly, there is continued interest in the development of new devices and methods for the patient-controlled delivery of medication via a pump which provide even greater flexibility to accommodate the real-time, immediate needs of each patient and to particularly control the real-time delivery of such medication. Of particular interest would be the development of a patient-controlled medication delivery system which provides the patient with such flexibility and control while increasing convenience and ease of use, enhancing portability and providing improved patient privacy when needing to interface with the medication delivery system. [0005]
  • SUMMARY OF THE INVENTION
  • Devices, systems and methods are provided for remotely controlling medication delivery to a patient by means of a medication infusion pump, such as a subcutaneous infusion pump, and/or for remotely controlling the measurement of physiological fluid, such as blood or interstitial fluid, of a patient by means of a percutaneous physiological fluid monitoring device. The systems of the present invention include a hand-held “fob” for the remote control of the infusion pump and/or the monitoring device. The infusion pump and monitoring device may be separately housed or integrated into a single housing structure. [0006]
  • The infusion pump includes a medication reservoir and a drive motor for dispensing the medication from the reservoir. The infusion pump may further include a power supply and a battery, an alarm, a digital display, a pump controller having a microprocessor for controlling pump operation and pump communication functions, a communication module for the bidirectional communication with the fob and other devices, memory storage means for the short-term or long-term storage of data, and control keys to enter or select data or parameters from menus displayed on the display. [0007]
  • The physiological fluid monitoring device includes a fluid sampling means for accessing and collecting blood or interstitial fluid from the patient and a characteristic measurement means for monitoring one or more characteristics, e.g., analytes, of the sampled fluid. The sampling and subsequent monitoring of the physiological fluid may be done on a substantially continuous basis. The physiological fluid monitoring device may further include a power supply and a battery, an alarm, a digital display, a communication module for the bi-directional communication with the fob and other devices, memory storage means for the short-term or long-term storage of data, and user interface control keys to allow the user to enter or select data or parameters from menus displayed on the display. The physiological fluid monitoring device further includes a controller having a microprocessor for controlling operation of the sampling and measurement means, for controlling the receipt and transmission of signals via the communication module and for processing and transferring data between components within the monitoring device. A feature of the physiological fluid monitoring device is that it may be programmed to provide for the continuous, on-going access, collection and measurement of physiological fluid without the need for human intervention. [0008]
  • The fob includes means for the remotely controlling the pump and/or the continuous physiological fluid collection and monitoring device. Optionally, the fob may also include a “non-continuous” or episodic physiological fluid measurement meter. The fob has a test strip port configured to receive a test strip for the episodic measurement the blood glucose concentration of a sample of the patient's blood by the meter. The fob also contains components which allow a user to remotely control the infusion pump and the physiological fluid collection device, including a fob controller having a microprocessor for controlling pump and meter operation functions and a communication module for communicating pump operation, a display and control keys for the entering, selection and transmission of data to the pump and the physiological fluid collection device, and memory storage means for the storage of such data. [0009]
  • An advantage of the subject system over many conventional insulin delivery and monitoring systems, is the consolidation of an episodic blood chemistry meter and features for the very discrete, remote control of an insulin pump and/or a continuous-measurement analyte tester within a very small, stand-alone fob. In addition to remotely controlling the insulin pump and the continuous measurement analyte tester, the fob provides for the consolidation of blood chemistry data and insulin delivery data over a period of time and maintains such consolidated data for immediate and later retrieval by the user or a physician. As such, a comprehensive analysis can be made of all key information and events affecting the treatment of a patient. [0010]
  • Such advantages are provided by certain features of the subject system which allow a user broad flexibility in the monitoring and in the control of blood glucose levels. Specifically, subject system provides the user with the ability to make changes to bolus and basal rate delivery default parameters at any time. Much of this flexibility is provided by software algorithms for the control and setting of medication boluses. [0011]
  • To better treat a user's immediate and ongoing needs, the present invention allows a user to customize an insulin bolus delivery protocol, i.e., bolus volume and delivery duration, by factoring in or compensating for the user's current or substantially current blood chemistry evaluation and/or the user's anticipated and/or actual carbohydrate intake. More specifically, the present invention provides three calculator function options, namely the carbohydrate calculator function, the blood glucose calculator function and the combined calculator function, which allow the user the option to take into consideration either or both blood chemistry and carbohydrate intake, as well as other factors such as exercise undertaken by the user, prior to implementing a bolus delivery protocol. Certain of the parameters for making such calculations are defaults values, e.g., the bolus-to-carbohydrate ratio, bolus to blood glucose ratio, and the user's target blood glucose level, which have been preprogrammed into the systems' controllers, while other parameters, e.g., the user's actual blood glucose level, the amount of carbohydrates to be consumed, and the bolus dosage correction factors, are to be entered on a real-time basis by the user. [0012]
  • The methods of the present invention involve the remote control of a medication insulin pump and a physiological fluid monitoring device by means of a fob, as described above. Such remote control involves “handshaking” between the pump and the fob and between the monitoring device and the fob (and optionally between the pump and the monitoring device) wherein data and commands are communicated back and forth between the various devices via their respective communication modules. [0013]
  • The methods may involve the implementation of one or more of various types of bolus delivery algorithms which include a standard bolus delivery algorithm, an extended bolus delivery algorithm and a dual bolus delivery algorithm. Each of the above may be implemented with or without the above mentioned calculator functions in order to customize and optimize each bolus delivery protocol at any one given time. [0014]
  • These and other objects, advantages, and features of the invention will become apparent to those persons skilled in the art upon reading the details of the methods and systems of the present invention which are more fully described below.[0015]
  • BRIEF DESCRIPTIONS OF THE DRAWINGS
  • FIG. 1 illustrates a system of the present invention having a portable medication delivery pump to be worn by the patient and a blood characteristic meter configured in the form a remote control device for controlling the functions of the meter and the pump. [0016]
  • FIG. 1A is a view of the pump of FIG. 1 taken along the lines A-A in FIG. 1. [0017]
  • FIG. 1B is a view of the remote control-meter device of FIG. 1 taken along the lines BB in FIG. 1. [0018]
  • FIG. 2 is a block diagram of the system of FIG. 1. [0019]
  • FIG. 3A is a flow chart of the standard bolus delivery algorithm of the present invention. [0020]
  • FIG. 3B is a flow chart of the extended bolus delivery algorithm of the present invention. [0021]
  • FIG. 3C is a flow chart of the dual bolus delivery algorithm of the present invention. [0022]
  • FIG. 4A is a flow chart of the carbohydrate calculator mode algorithm of the present invention. [0023]
  • FIG. 4B is a flow chart of the blood glucose calculator mode algorithm of the present invention. [0024]
  • FIG. 4C is a flow chart of the carbohydrate/blood glucose calculator mode algorithm of the present invention. [0025]
  • FIG. 5 is a flow chart of a method of the present invention. [0026]
  • FIG. 6 illustrates another system of the present invention having a portable continuous physiological fluid monitoring device to be worn by the patient and a remote control device for controlling the functions of the monitoring device, which remote control device also provides an integral meter for physiological fluid monitoring. [0027]
  • FIG. 7 illustrates the continuous physiological fluid monitoring device of the system of FIG. 6 including a disposable cartridge used with the monitoring device. [0028]
  • FIG. 8 illustrates an enlarged perspective view of the cartridge of FIG. 7. [0029]
  • FIG. 9 is a block diagram of the system of FIG. 6. [0030]
  • FIG. 10 is a block diagram of another system of the present invention which includes a portable medication delivery pump, a continuous physiological monitoring device and a remote control for controlling the functions of the delivery pump and the monitoring device.[0031]
  • DETAILED DESCRIPTION OF THE INVENTION
  • Before the present invention is described, it is to be understood that this invention is not limited to the particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims. [0032]
  • Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention. [0033]
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. [0034]
  • It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a test strip” includes a plurality of such test strips and reference to “the device” includes reference to one or more devices and equivalents thereof known to those skilled in the art, and so forth. [0035]
  • The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided might be different from the actual publication dates which may need to be independently confirmed. [0036]
  • The present invention will now be described in detail. In further describing the present invention, the subject systems and device components will be described first. Next, various methods of using the subject devices and systems as well as methods for controlling the testing of physiological sample characteristics and for controlling the delivery of medication to a patient will then be described. Finally, a brief description is provided of the subject kits, which kits include the subject devices and systems for use in practicing the subject methods. [0037]
  • In the following description, the present invention will be described in the context of glucose concentration measurement and insulin delivery applications; however, such is not intended to be limiting and those skilled in the art will appreciate that the subject devices, systems and methods are useful in the measurement of other physical and chemical characteristics, e.g., blood coagulation time, blood cholesterol level, etc., of biological substances and in the delivery of other medications and the like, e.g., pain control medication, antibiotics, chemotherapy and nutritional therapy. [0038]
  • Systems and Devices [0039]
  • Referring now to the drawings, FIGS. 1 and 2 illustrate a system of the present invention having an infusion pump [0040] 4 and a remote control device 6, commonly referred to as a “fob.” FIG. 1A shows a top view of pump 4 along the line A-A and FIG. 1B shows a side view of device 6 along the line B-B. FIG. 2 illustrates block diagrams of pump 4 and fob 6 and their respective components. FIGS. 6-9 illustrate another system of the present invention having a physiological fluid monitoring device 300 and a fob 350. FIGS. 6-8 illustrate external views of the components of the system and FIG. 9, along with FIG. 10, provide block diagrams of the monitoring device 300 and fob 350. FIG. 10 illustrates another system of the present invention which includes both a pump and a monitoring device.
  • Infusion Pump [0041]
  • Infusion pump [0042] 4 has a housing 8, preferably formed from a durable plastic material, having a portion 8 a adapted to receive or house a syringe or reservoir (not shown) holding prescribed medication for administration to the patient via an associated indwelling infusion tubing or catheter 10. Housing 8 is preferably sufficiently compact so as to be comfortably and discretely carried by the user, for example, by means of a belt clip or the like. Generally, housing 8 has a length Lp in the range from about 2.5 to about 5 inches and more typically from about 3 to about 3.5 inches, a height HP in the range from about 1.5 to about 3 inches and more typically from about 2 to about 2.5 inches, and a thickness TP in the range from about 0.5 to about 1.5 inches and more typically from about 0.75 to about 1 inch. While pump 4 is illustrated having a substantially rectangular or square shape, it may have any appropriate shape, for example, circular, oblong, etc.
  • Infusion pump [0043] 4 houses many of the same basic components and construction as prior art infusion pumps, such as those disclosed in U.S. Pat. Nos. 4,562,751, 4,678,903, 5,080,653, 5,097,122, 5,935,099, 6,248,093 B1 and 6,406,605 B1 which are herein incorporated by reference. Such basic components include a medication reservoir 50 and a drive motor 52 which uses a lead screw assembly for motor-driven advancement of a reservoir piston (not shown) to cause the medication to exit from a pump outlet into infusion tube 10; however, other suitable mechanisms for dispensing medication from reservoir 50 may be used such as, for example, electroosmotic flow (also referred to as electrokinetic flow). Additionally, a power supply 62 and a battery 64 are provided to supply the necessary electrical power for operating the components of pump 4.
  • Examples of electroosmotic pumps suitable for pumping a medication are disclosed in U.S. Pat. Nos. 6,406,605, 3,923,426 and PCT publication WO 02/094440. Basically an electro-osmotic pump comprises a pump medium to be wetted by the liquid to be pumped and a pair of electrodes to impose a voltage over the pump medium in the direction of flow. Often the pump medium is in the form of a porous membrane exhibiting a net electrical surface charge when wetted by the liquid to be pumped. The electric field set up between the electrodes results in a shifting of charged species in the liquid in the direct vicinity of the surface of the pump medium. This transport of charged species drags along the liquid to be pumped and results in the required liquid flow in direction of the electric field. Each of the disclosed pumps can be applied to either directly or indirectly pump the medication. In direct pumping, the medication flows though the pump medium whilst in indirect pumping a second liquid is pumped through the pump medium and the displacement of this second liquid is applied to pressurize and drive the medication to be delivered. [0044]
  • Pump [0045] 4 may further include audio, visual and/or vibration alarm/reminder means 66 for alerting the user to an alarm condition, e.g., when a low volume of medication is remaining in the reservoir, a blood chemistry measurement which is outside the acceptable range, low battery power, when an occlusion occurs in the infusion tubing, when there is a malfunction in the pump, or for reminding the user of an event or to perform a necessary action, e.g., perform a blood chemistry evaluation, enter medication delivery protocol, etc. or some other user-definable alert. Suitable alarm/reminder means 66 for use with pump 4 may include audio means, e.g., a piezoelectric beeper; motion means, e.g., a vibration motor; and/or visual means, e.g., an LED, etc.
  • Pump [0046] 4 also includes a display 14, such as a liquid crystal display (LCD), for graphic and alphanumeric display. Such graphic display may include icons representative of, for example, bolus and basal rate delivery status and settings, historical data regarding blood glucose levels and insulin deliveries stored in memory, stop bolus commands, etc. Selecting an icon will bring up the corresponding user interface menu.
  • Pump [0047] 4 further includes a pump controller 54 having a microprocessor for controlling pump operation and pump communication functions. Pump controller 54 may also have a memory element for storing pump operation software programs and other static data such as pre-programmed default values including but not limited to blood chemistry meter calibration information, user preferences, e.g., language, user basal rate, carbohydrate and blood glucose bolus correction factors, a user's target blood glucose level, calculator, etc.
  • A memory storage means [0048] 56 is provided for the temporary storage of dynamic data such as pump infusion data, blood chemistry data (acquired by meter/sensor 80 of fob 6) and other data entered by the user. Pump infusion data may include information such as the medication delivery rate (Units/Hour), the current volume of medication held in the reservoir, bolus delivery start/stop time, bolus delivery duration, etc. Blood chemistry data includes the blood glucose concentration (mg/dL) measurements and their respective dates and times. Other data that may be entered by the user via control keys 12 include but are not limited to carbohydrate intake (mmol/L) and the parameters related to bolus deliveries, e.g., bolus dosage, bolus duration, bolus start and stop times, etc.
  • Pump [0049] 4 further includes control keys 12 a, 12 b and 12 c to allow the user to enter or select data or parameters from a menu displayed on display 14. For example, control key 12 a may have a jogwheel configuration, as illustrated in FIG. 1A. More specifically, jogwheel 12 a is rotated by the user to select the desired volume of the medication bolus to be delivered by pump 4. Jogwheel 12 a may also be used to scroll through menu items from display 14 and to select such menu items by depressing jogwheel 12 a. Control keys 12 b and 12 c may be configured as depressible buttons for initiating the communication of data to and from fob 6 or other auxiliary devices and for initiating a bolus delivery. Pump 4 may have any number of control keys, each having any suitable configuration, e.g., jog wheel, depressible button, keypad, etc., for controlling pump 4.
  • Commands and data are communicated to and from pump controller [0050] 54 via one-way and two-way data lines or buses 72 and 74, respectively. More specifically, pump controller 54 receives electrical power from power supply 62 and battery 64, receives input data and commands from the user via control keys 12, and transmits commands to alarm/reminder means 66 on one-way lines 72; otherwise, communication between pump controller 54 to and from the various components of pump 4 is accomplished by two-way lines 74. The communication of information between pump 4 and fob 6 and other external devices is described in greater detail below.
  • Pump Remote Control/Blood Chemistry Meter (“Fob”) [0051]
  • Fob [0052] 6 includes an episodic blood characteristic measurement sensor or meter and means for the remote control of pump 4. Fob 6 has a housing 20, preferably formed from a durable plastic material and having a very compact size and an ergonomic shape so as to be discretely carried in one's clothing, such as a pocket, or held in one's hand. Generally, fob 6 has a size no greater than about one-third the size of pump 4. Fob housing 20 has a length LF in the range from about 1.5 to about 4 inches and more typically from about 2 to about 2.5 inches, a width WF in the range from about 0.75 to about 2 inches and more typically from about 1 to about 1.5 inches, and a thickness TF in the range from about 0.25 to about 1 inch and more typically from about 0.5 to about 0.75. While fob 6 is illustrated as having a substantially oblong or elliptical shape, it may have any shape, e.g., circular, etc., preferably an ergonomic shape. Fob 6 may be further configured, such as at its proximal end 28, to provide attachment to an accessory ring 22, which may be used to secure fob 6 to an item of clothing or to keys and the like.
  • At the fob's distal end [0053] 30 is a test strip port 32 configured to receive a test strip 40, such as an electrochemical, colorimetric or photometric test strip used in analyte concentration determination, such as the glucose concentration in a sample of blood taken from a user. Housed within fob 6 is a meter 80 for making such determinations. Test strip port 32 and meter 80 may also be configured to receive a calibration strip or the like for calibrating meter 80.
  • Examples of electrochemical test strips suitable for use with the subject invention include those described in copending U.S. application Ser. Nos. 09/497,269; 09/736,788 and 09/746,116, U.S. Pat. Nos. 6,475,372; 6,193,873; 5,708,247; 5,951,836; 6,241,862; 6,284,125; and 6,444,115, and International Patent Application Publications WO/0167099; WO/0173124; WO/0173109; and WO/0206806, the disclosures of which are herein incorporated by reference. Examples of colorimetric or photometric test strips suitable for use with the subject invention include those described in U.S. Pat. Nos. 5,563,042; 5,753,452; and 5,789,255, herein incorporated by reference. Certain aspects of the functionality of electrochemical meters suitable for use with the subject systems are disclosed in U.S. Pat. No. 6,193,873, as well as in copending, commonly owned U.S. application Ser. Nos. 09/497,304, 09/497,269, 09/736,788, 09/746,116 and 09/923,093, the disclosures of which are herein incorporated by reference. Certain aspects of the functionality of colorimetric/photometric meters suitable for with the present invention use are described in, for example, U.S. Pat. Nos. 4,734,360, 4,900,666, 4,935,346, 5,059,394, 5,304,468, 5,306,623, 5,418,142, 5,426,032, 5,515,170, 5,526,120, 5,563,042, 5,620,863, 5,753,429, 5,773,452, 5,780,304, 5,789,255, 5,843,691, 5,846,486, 5,968,836 and 5,972,294, the disclosures of which are herein incorporated by reference. [0054]
  • In addition to housing test strip meter [0055] 80, fob 6 contains components which allow a user to remotely control infusion pump 4. Such components include a fob controller 82 which, similar to pump controller 54, includes a microprocessor for controlling pump and sensor/meter operation functions and for communicating pump operation functions and blood chemistry information to pump 4 or to another external device from fob 6. Fob controller 82 may also have a memory element for storing pump and sensor operation software programs.
  • Fob [0056] 6 further includes a memory storage means 84 for the storage of dynamic data such as blood chemistry data and other data entered by the user. Memory storage means 84 stores a limited number, about 10, more or less, of the latest blood chemistry measurements and corresponding dates and times of such measurements, event-specific user parameters, e.g., exercise duration, carbohydrate intake, etc.
  • Control keys [0057] 24, which may have a jogwheel and/or depressible button configurations similar to control keys 12 of pump 4, allow a user to enter or select data from program menus displayed on a display 26, such as a liquid crystal display (LCD), for displaying graphic and alphanumeric information. Typically, a jogwheel is used to select or retrieve data or to select a bolus delivery program or parameters to be implemented. A depressible button is most often used to transmit data, e.g., glucose results, bolus delivery commands, silence alarm commands, terminate bolus delivery commands, etc., to pump 4 or to another external device. The data entered or selected by the user via control keys 24 is sent to controller 82 for implementing a sensor or pump function or otherwise storing such data in memory storage means 84. Fob 6 may have any number of control keys, each having any suitable configuration, e.g., jogwheel, depressible button, key pad, etc.
  • Data that may be entered by the user via control keys [0058] 24 includes, but is not limited to, carbohydrate intake (grams), the desired bolus delivery program and the parameters related to bolus deliveries, e.g., bolus dosage, bolus duration, bolus start and stop times, type of medication, amount of medication, target gluocse range (both upper and lower), exercise intensity, exercise duration, health comments, food type, food amount, HbA1c, blood pressure, and other data as disclosed in Great Britain Patent No. GB0212920.3, etc., as well as the provision of a user-operated calculator for determining and setting the appropriate bolus volume.
  • Commands and data are communicated to and from fob controller [0059] 82 via one-way and two-way data lines or buses 94 and 96, respectively. More specifically, fob controller 82 receives electrical power from power supply 86 and battery 88 and receives input data and commands from the user via control keys 24 on one-way lines 94; otherwise, communication between fob controller 82 to and from the various components of fob 6 is accomplished by two-way lines 96. The communication of information between fob 6 and pump 4 and other external devices is described in greater detail below.
  • Continuous Physiological Fluid Monitoring Device [0060]
  • FIG. 6 illustrates another system of the present invention including a continuous physiological fluid monitoring device [0061] 300 and a remote control device 350. Remote control device or fob 350 may be similar to the structure and function of fob 6 as described above, and may optionally include a physiological fluid measurement meter for the non-continuous or episodic analyte testing of physiological fluid. As such, fob 350 is provided with a test strip port 352 for receiving a test strip 40, as described above. As with fob 6, fob 350 has a low-profile housing 358, a display 354, control keys 356 and the same or similar internal componentry (not shown).
  • Monitoring device [0062] 300 also has a low profile housing 360 and a strap 362 which allows it to be worn on a limbic region such as the arm. In FIG. 6, device 300 is shown worn around a patient's upper arm but may also be configured to be worn around the forearm or wrist. Monitoring device 300 is also provided with a display 364 and control keys 366 similar to the displays and control keys described above. As shown in FIG. 7, the underside or skin-contacting side 368 of housing 360 is configured with an insertion cavity 382 to receive a disk-shaped, disposable cartridge 380 which includes a fluid sampling means 302 operatively connected and in fluid communication with a measurement sensor or means 304 housed within the cartridge. The measurement sensor 304 may have an electrochemical or-photometric/colorimetric configuration and have the ability to measure glucose semi-continuously or continuously similarly to those meters disclosed in WO 02/49507A1, which is incorporated herein in its entirety. In the embodiment of FIG. 7, the measurement sensor has an electrochemical configuration with electrical communication established between the sensor and the electronics of monitoring device 300 by means of a set of electrical contact pad pairs 384 on the circumference of cartridge 380 and corresponding electrical contact pins 386 within insertion cavity 382.
  • FIG. 8 illustrates an enlarged perspective view of cartridge [0063] 380. Cartridge 380 is formed of a molded base 392 having a disk shape and having a diameter in the range from about 20 mm to about 40 mm, and more typically about 35 mm, and a thickness in the range from about 0.1 mm to about 3 mm, and more typically about 2 mm.
  • A sampling means [0064] 302 in the form of a needle 410 and a pressurizing ring 412 are provided on the bottom surface 390 of base 302. Needle 410 is used to penetrate the skin of the user and for accessing and extracting physiological fluid. Needle 410 has an inner diameter in the range from about 0.1 mm to about 0.5 mm is most typically about 0.3 mm (25 gauge). Pressurizing ring 412 functions to stabilize and pressurize the area of skin surrounding the penetration site in order to actively facilitate the extraction of ISF into needle 410. To accomplish these functions, pressurizing ring 412 typically has a diameter in the range from about 5 mm to about 30 mm, and more typically has a diameter of about 12 mm. Needle 410 is housed is positioned at its proximal end within a recess (not shown) of pressurizing ring 412. Needle 302 preferably has a penetration length dimensions which allows it to penetrate the skin to a depth which minimizes the pain felt by the user. The depth of the recess determines the maximum penetration depth of needle 410. As such, 410 needle may be configured and positioned relative to pressurizing ring 412 to penetrate only into but through the dermis layer of skin where there is substantially blood free interstitial fluid (ISF), typically to a depth from about 1.5 mm to about 3.0 mm below the skin surface.
  • Preferably, needle [0065] 410 and pressurizing ring 412 move and are applied to the skin independently of each other. In practice, a driving means, such as a spring, is used to urge pressure ring 412 against the skin, and a second driving means, such as a second spring, is used to launch needle 410 into the skin. While such mechanisms are not specifically illustrated or described herein, such mechanisms are known by those skilled in the art.
  • Needle [0066] 410 is in fluid communication with at least one or more sensors or detectors housed within cartridge 380 to carry out the analyte measurement function of device 300. Suitable cartridges or the like for use with monitoring device 300 are disclosed in commonly owned and assigned International Publication WO 02/49507, which is incorporated herein in its entirety.
  • FIG. 9 provides a schematic illustration of the function of system of FIG. 6. As shown in FIG. 9, the system generally includes monitoring device [0067] 300 and remote control fob 350. Monitoring device 300 includes a disposable cartridge 380 electronically interfaced with a controller 306. Cartridge 380, as mentioned above, includes a sampling means 302 in fluid communication with a sensor means 304. Sampling means 302 has fluid access means, such as a needle, external to the device housing for extracting physiological fluid, e.g., ISF, from the body. In operation, fluid accessed in the skin is transferred 450 into the fluid collection areas of the sampling means 302. The sampled fluid is then transferred 452 into the sensor means 304 where the selected analyte is measured. Signals representative of the measurement values are input 454 to controller 306 which controls fluid sample measurement operation via output signals 456 (see FIG. 10). Representations of those values are then displayed on display 364 for observation by the user. This data is then also communicated to remote control fob 350 via bi-directional communication signals 325, described in greater detail below. As mentioned above, fob 350 may also be provided with a sensor mechanism for measuring analyte concentration from sampled fluid 458, typically blood, applied to a test strip and inserted 460 into fob 350 for testing by the sensor mechanism. The remote sensor of fob 350 may be used for calibrating the local sensors of monitoring device 300.
  • FIG. 10 further illustrates the internal componentry of monitoring device [0068] 300. As mentioned above, controller 306 has a microprocessor for controlling fluid sample measurement operation and communication between components of device 300 and for controlling communication between monitoring device 300 and fob 350 via bidirectional communication protocol 325. Controller 306 may also have a memory element for storing sensor operation software programs and other static data such as pre-programmed default values including but not limited to sensor calibration information, alarms, and unit identification/serial number.
  • Measurement device [0069] 300 may further include audio, visual and/or vibration alarm/reminder means 308 for alerting the user to an alarm condition, e.g., when blood glucose levels falls outside the acceptable range, when battery power is low, when the fluid sample or sensor is malfunctioning, or for reminding the user of an event or to perform a necessary action, e.g., replacing the sampling means. Suitable alarm/reminder means 308 may include audio means, e.g., a piezoelectric beeper; motion means, e.g., a vibration motor; and/or visual means, e.g., an LED, etc.
  • Measurement device [0070] 300 also includes a display 364, such as a liquid crystal display (LCD), for graphic and alphanumeric display of data such as sample fluid test results, e.g., blood glucose levels, and calibration results. A memory storage means 312 is provided for the temporary storage of dynamic data such as blood chemistry data acquired by sensor means 304 and data entered by the user. Blood chemistry data includes the blood glucose concentration (mg/dL) measurements and their respective dates and times. Other types of data storable on memory storage means 312 includes but are not limited to the type of medication, amount of medication, target gluocse range (both upper and lower), exercise intensity, exercise duration, health comments, food type, food amount, HbA1c, blood pressure, etc. Additionally, a power supply 314 and a battery 316 are provided to supply the necessary electrical power for operating the components of measurement device 300.
  • Measurement device [0071] 300 further includes control keys 366 to allow the user to enter or select data or parameters from a menu displayed on display 364, such as inputs for turning the device on and off, temporarily suspending operation, turning off RF transmission (in restricted areas), alarm acknowledgement and reset, and synchronizing communications with other devices. As with the control keys of pump 4 and fob 6, control keys 366 may have any number of control keys, each having any suitable configuration, e.g., jog wheel depressible button, keypad, etc., for controlling measurement device 300.
  • Commands and data are communicated to and from controller [0072] 306 via one-way and two-way data lines or buses 320 and 322, respectively. More specifically, controller 306 receives electrical power from power supply 314 and battery 316, receives input data and commands from the user via control keys 318, and transmits commands to alarm/reminder means 308 on one-way lines 320; otherwise, communication between controller 306 to and from the various components of measurement device 300 is accomplished by two-way lines 322. The communication of information between measurement device 300 and fob 350 and other external devices is described in greater detail below.
  • The systems of the present invention may include both an infusion pump [0073] 4 as well a continuous physiological fluid monitoring device 300, as illustrated in FIG. 10, where bi-directional communication 340 between pump 4 and device 300 is also provided. While infusion pump 4 and measurement device 300 have been described as separate components, the medication delivery and physiological sampling and measurement components and functions may be combined into an integrated device whereby they share power, controller. alarm, display, memory and communication components. Such an integrated unit provides the advantage of requiring the patient to carry or wear only one piece of hardware rather than two.
  • Communication and Data Transmission [0074]
  • The bidirectional communication (designated by reference number [0075] 15 in FIG. 2, reference number 325 in FIGS. 9 and 10 and reference number 340 in FIG. 10) and transfer of data between pump 4 and fob 6 and between measurement device 300 and fob 350 may be accomplished by any suitable means, e.g. radio frequency (RF) transmission, infrared (IR) transmission, etc. For example, pump 4 and fob 6 may each have an RF communication module 68 and 92, respectively, which are controlled by their respective controllers, allowing bidirectional communication between the two devices provided the devices are within a maximum range of each other. Typically, such range is within about 0 to about 10 ft and more typically within about 0 to about 4 ft, and usually no more than about 25 feet. Similarly, measurement device 300 may have an RF communication module 324 controlled by controller 306 which provides for bi-directional communication between the measurement device 300 and fob 350. Additionally, pump 4 and measurement device 300 may communicate directly with each other in the same bi-directional manner or through a fob. In systems where the infusion pump and measurement devices are integrated into a single unit, communication is handled by a common controller or microprocessor.
  • Modules [0076] 68, 92 and 324 are configured and programmed to “link” a particular pump unit and/or measurement device to a particular fob unit to prevent unintentional communications between the fob and other infusion pumps and measurement devices within the same frequency range. The communication protocol between a pump-fob or measurement device-fob or pump/measurement device-fob combination may be configured so as to provide an address associated with the pair which precedes every data transmission between the two so as to prevent inadvertent transmissions between one user's system and another user's system. The modules may be further configured to link a fob to more than one pump and/or measurement device belonging to the same user, as some users have more than one pump. Likewise, the modules may be programmed to link one pump and/or measurement device to more than one fob belonging to the same user.
  • While the majority of data and information transferred between pump [0077] 4 and fob 6 is initiated by the user, there are certain communications between the two devices which are automatic and do not require user intervention. The modules may be configured, for example, such that blood chemistry data and user preference information, e.g., language, bolus limits, etc., is periodically sent from the fob to the pump or from the pump to the fob, or is automatically sent upon turning on the fob. Also, the modules may be configured such that medication infusion information, e.g., historical basal rate and bolus delivery data, is periodically sent from the pump to the fob.
  • Similarly, information regarding the patient's blood glucose levels, as monitored by measurement device [0078] 300, may be automatically communicated on either a continuous or periodic basis to fob 350. Particularly in those embodiments of measurement device 300 where an alarm means is not provided, fob 6 may be provided with an alarm and alert the patient when the patient's blood glucose level falls outside an acceptable range which may be defined by a user or a doctor. The system may be programmed to automatically adjust the then in process insulin delivery protocol or prompt the patient to override the protocol via inputs to fob 350.
  • The system may be further configured such that pump [0079] 4 and measurement device 300 are able to communicate with each other. Where pump 4 and measurement device 300 are separate components, they may communicate by means of bi-directional communication 340 similar to the manner in which pump and fob 6 communicate with each other. In an integrated unit, the functions of medication delivery pump and the fluid sampling and measurement means are controlled by a common controller (not shown). In either case, the system may be programmed such that medication protocol implemented by pump 4 is automatically adjusted based on the analyte measurement levels determined by measurement device 300 via commands to and from fob 6. Such may be accomplished without any intervention by the patient and even without the patient being notified or otherwise aware of the adjustment in protocol.
  • Each of pump [0080] 4, fob 6 or 350 and measurement device 300 may optionally include communication modules and/or input/output ports 70, 90 and 326, respectively, (such as an RS232 (IEEE standard) or a Universal Serial Bus (USB)) for communicating with external devices such as personal computers (PC), personal digital assistants (PDAs) and the like. In an embodiment of this invention, the communication modules may use a wireless communication method such as a Bluetooth or a Wi-Fi 802.11 scheme. For example, the data stored in either or each of the pump, the fob or the measurement device's controller and memory storage means may be downloaded to an external computer for detailed review and analysis or further processing by a physician to determine, for example, the effectiveness of the drug regime, patient compliance or trends in the patient's glucose levels. Conversely, the physician may use an external computer to download software programs and operational parameters, e.g., the patient's basal rate and certain customized target values, ranges, reminders and alarms, to the pump and/or fob controllers. Communication between the devices of the present invention and external devices may be provided by telemetry transmission, e.g., RF, IR, etc., or data port technologies, e.g., modem, cable, etc.
  • In an embodiment of the invention, fob [0081] 6 also incorporates a portion of storage means 84 that will allow future updates (“field upgrade”) of the operating system and or other software elements. Preferably, a portion of storage means 84 is of the type “flash memory” which does not need a electrical energy in order to securely store its contents.
  • Fob [0082] 6 may further comprise a communication slot (not shown) for receiving a data-carrying element and communicating therewith. This data-carrying element preferably is a ‘SIM’ card type device. A single use data-carrying element is provided with or on every disposable cartridge, and contains production lot specific data (calibration data, identification number etc.). The data-carrying element is read-out by the remote controller and the data received therefrom is applied in the interpretation of the ISF glucose data received from fob 6.
  • Software Algorithms [0083]
  • Each of the components of the subject systems is provided with software which enables the components to perform their various functions and to communicate with each other. Certain features and algorithms of the software used with the present invention is provided in detail below. [0084]
  • An advantage of the subject system over many conventional insulin delivery systems, is the consolidation of a blood chemistry meter and features for the remote control of an insulin pump within a very small, stand-alone device such as the fob just described. In addition to remotely controlling the insulin pump and the measurement device, the fob provides for the consolidation of blood chemistry data and insulin delivery data over a period of time and maintains such consolidated data for immediate and later retrieval by the user or a physician. As such, a comprehensive analysis can be made of all key information and events affecting the treatment of a patient. [0085]
  • Such advantages are provided by certain features of the subject system which allow a user broad flexibility in monitoring and in the control of blood glucose levels. Specifically, subject system provides the user with the ability to make changes to bolus and basal rate delivery default parameters at any time. Much of this flexibility is provided by software algorithms for the control and setting of medication boluses. [0086]
  • Controller [0087] 54 of pump 4 and controller 82 of fob 6 are programmed with software that supports several types of bolus delivery protocols: standard, extended and dual. The standard or “quick” bolus delivery protocol allows the user to select a dosage of medication for immediate infusion of the entire bolus. The user is likely to require such a quick bolus delivery immediately prior to a meal or snack that includes simple carbohydrates, e.g., fruits, etc. The extended bolus delivery protocol allows the user to select a dosage of medication for infusion over a selected period of time within in a certain time range. An extended bolus delivery protocol is typically implemented prior to a meal that includes a sizable portion of complex carbohydrates, e.g., starches, etc. The dual bolus delivery protocol combines the above two protocols, allowing a user to consecutively implement both a quick bolus and an extended bolus in a single command sequence. A dual bolus delivery protocol is typically implemented prior to eating a meal containing both simple and complex carbohydrates.
  • To better treat a user's immediate and ongoing needs, the present invention allows a user to customize an insulin bolus delivery protocol by factoring in or compensating for the user's current or substantially current blood chemistry evaluation and/or the user's anticipated and/or actual carbohydrate intake. More specifically, the present invention provides three calculator function options, namely the carbohydrate calculator function, the blood glucose calculator function and the combined calculator function, which allow the user the option to take into consideration either or both blood chemistry and carbohydrate intake, as well as more minor factors such as exercise undertaken by the user, prior to implementing a bolus delivery protocol. While all three bolus delivery algorithms may provide for all three calculator function options, typically it is not appropriate to factor in blood chemistry data for extended bolus deliveries (either alone or in combination with a quick bolus delivery) as blood chemistry is likely to change after a relatively short period of time, i.e., prior to the completion of an extended bolus delivery. [0088]
  • FIGS. 3A, 3B and [0089] 3C respectively illustrate block diagrams of the three bolus delivery algorithms of the present invention, while FIGS. 4A, 4B and 4C respectively illustrate block diagrams of the calculator function options of the present invention. In further describing the present invention, each of the three delivery algorithms will first be described in the context where no calculator function options are used, followed by a description of the three calculator functions as they apply to the standard and extended delivery algorithms. Whereas such algorithms may be implemented through the user's interface with either the pump or the fob, the following description is in the context of a user's interface with the fob, the more likely scenario.
  • A. Bolus Delivery Algorithms
  • 1. Standard Bolus Delivery Algorithm [0090]
  • As shown in the block diagram of FIG. 3A, upon selecting the standard insulin bolus delivery program [0091] 100 from a bolus function menu (see step 246 of FIG. 5) displayed on the fob, the user is requested to set the standard bolus dosage (SDOS) 102 he or she desires to be administered. So as to prevent over-dosing, the algorithm will only implement the bolus delivery if the units entered are less than about a maximum amount (SMAX U) 104, which SMAX U will vary depending on the individual user's body mass and metabolism. For a user having an average body mass and metabolism, SMAX U will be about 10 Units. However, the SMAX U is likely to be lower for children and greater for obese users. SMAX U may be set as a default value upon the initial programming of the subject system or may be changed by the user during the programming of a particular standard bolus. Steps 102 and 104 are shown collectively referenced as 126 for purposes of describing the steps of FIG. 3C, described below. Once the bolus dosage has been set within proper limits, the user is prompted to initiate the customized bolus delivery 106. Upon initiating such SDOS delivery, the entire SDOS is immediately delivered 108 to the user.
  • 2. Extended Bolus Delivery Algorithm [0092]
  • As shown in the block diagram of FIG. 3B, upon selecting the extended bolus delivery, program [0093] 110 from a bolus function menu (see step 246 of FIG. 5) displayed on the fob, the user is requested to set the extended insulin bolus dosage (EDOS) (Units) 112 he or she desires to be delivered. So as to prevent over-dosing, the algorithm will only implement the bolus delivery if the EDOS value entered is less than a maximum amount (EMAX U) 114, which, as explained above, will vary depending on the individual user's body mass and metabolism. Next, the user is prompted to enter the desired duration of the extended bolus delivery (DTIME) 116 which time period ranges from a minimum time (MIN T) to a maximum time (MAX T). Such DTIME may range from about 1 minute to 24 hours but more typically ranges from about 30 minutes to 8 hours, for example. If the DTIME value entered is outside the acceptable range 118, the user is prompted to re-enter an acceptable value. Steps 110, 112, 114, 116 and 118 are collectively referenced as 128 for purposes of describing the steps of FIG. 3C, described below. Once these two parameters have been set within acceptable limits, the user is prompted to initiate the customized extended bolus delivery 120. Upon initiating such EDOS delivery, the EDOS is delivered to the user over DTIME 122.
  • 3. Dual Bolus Delivered Algorithm [0094]
  • As shown in the block diagram of FIG. 3C, upon selecting the dual bolus delivery program from a bolus function menu (see step [0095] 246 of FIG. 5) displayed in the fob, the user is requested, as in the standard bolus delivery algorithm at 126 on FIG. 3A, to set the standard bolus dosage (SDOS) (Units) he or she desires to be delivered having a value that is less than a maximum amount (SMAX U), as explained above. Next, as in the extended bolus delivery algorithm at 128 of FIG. 3B, the user is requested to set the extended insulin bolus dosage (EDOS) (Units) he or she desires to be delivered, again, having a value less than a maximum (EMAX U). Additionally, the user is prompted to enter the desired duration of the extended bolus delivery (DTIME) 128 within an acceptable time range, as explained above with respect to FIG. 3B. Once these two parameters have been set within acceptable limits, the user is prompted to initiate the delivery of both the SDOS and EDOS 130. Upon initiating such SDOS and EDOS deliveries, the complete SDOS is immediately delivered 132 to the user and, upon completion of the SDOS delivery 134, the EDOS delivery is initiated 136 and continues to be delivered to the user over DTIME 138.
  • B. Calculator Modes
  • 1. Carbohydrate Calculator Mode [0096]
  • Referring now to FIG. 4A, upon selecting the carbohydrate calculator mode (CARB CALC) [0097] 140, the user is first prompted to enter the anticipated or actual grams of carbohydrates (CARB) 142 he or she intends to imminently consume. Typically, the fob is programmed to accept no more than a preselected maximum carbohydrate value (MAX G) of about 200 g, a common MAX G value for adult users having an average body mass and metabolism, but may vary depending on the body mass and metabolism of the user. If the entered CARB value is greater than MAX G 144, the user is prompted to reenter an acceptable CARB value.
  • Based on a preprogrammed bolus dosage to carbohydrate ratio (B/C RATIO) (Units/g), which may be changed by the user at this point, the fob controller [0098] 82 then determines the dosage of insulin (XDOS) (Units) to be delivered 146, where XDOS may be either an SDOS or an EDOS. The B/C RATIO is typically within the range from about 1 Unit:30 g to 1 Unit:5 g but may be more or less depending on the user's condition and needs. The value of XDOS is the product of the CARB value and the B/C RATIO value (CARB x B/C RATIO).
  • After the B/C RATIO is set, the user is prompted to enter a carbohydrate correction factor (CARB CF) (Units) [0099] 148 to adjust the XDOS, i.e., to either decrease or increase the XDOS in order to fine-tune the bolus volume, for example, when the user anticipates exercising soon after a meal. The CARB CF value must be within a range from a minimum value (MIN CF) to a maximum value (MAX CF). For an average user, the CARB CF value typically ranges from about 0 Units to about 10 Units, but may be more or less depending on the user's needs. If the entered CARB CF value is outside an acceptable range 150, the user is prompted to reenter an acceptable CARB CF value.
  • Once all parameters have been set within proper limits, the fob prompts the user to initiate the XDOS delivery and, in turn, the user initiates the fob to send an XDOS delivery command [0100] 152 to the pump. The pump then initiates the XDOS delivery to the user 154.
  • 2. Blood Glucose Calculator Mode [0101]
  • Referring now to FIG. 4B, upon selecting the blood glucose calculator mode (BG CALC) [0102] 160, the fob prompts the user to enter his or her most recent blood glucose concentration level (ACTUAL BG) (mg/dL) 162 as measured by meter 80 of fob 6 or blood glucose concentration level of most recent blood glucose test can be automatically entered by the pump controller 82 if it was generated within a defined time frame. Optionally, the ACTUAL BG may be measured by physiological fluid measurement device 300 and transmitted directly to fob 6 which allows the BG CALC to be used at a higher frequency than if meter 80 were used alone. The ACTUAL BG value must be within the range from a minimum value (MIN ABG) to a maximum value (MAX ABG). For an average user, the ACTUAL BG value typically ranges from about 0 mg/dL to 600 mg/dL, but may be more or less depending on the user's needs. If the entered value is outside this range 164, the user is prompted to reenter an acceptable ACTUAL BG value.
  • The fob controller [0103] 82 then determines the standard bolus dosage of insulin (SDOS) (Units) to be delivered 166 which value is the product of the bolus to blood glucose ratio (B/BG RATIO) (Units/point, where one point is equal to 1 mg/dL) and the difference between the ACTUAL BG value and the user's targeted blood glucose level (TARGET BG) (mg/dL), as defined by the following equation: B/BG RATIO x (ACTUAL BG—TARGET BG)). The B/BG RATIO is a preprogrammed value, which value may, at this point, be changed by the user within a predefined range from a minimum value. For an average user, the B/BC RATIO typically ranges from about 1 Unit:150 pt to 1 Unit:10 pt, but may be more or less depending on the user's needs. The TARGET BG is also a preprogrammed value, which value may also be changed by the user within a predefined range. For an average user, the TARGET BG may be about 60 to 250 mg/dL, but may be more or less depending on the user's needs.
  • Next, the fob prompts the user to enter a blood glucose correction factor (BG CF) (Units) [0104] 174 to adjust the SDOS, i.e., to either decrease or increase the SDOS to fine-tune the bolus volume, for example, when the user anticipates exercising soon after a meal. The BG CF value must be within a range from a minimum value (MIN BGCF) to a maximum value (MAX BGCF). For an average user, the BG CF is typically from about 0 Units to 10 Units, but may be more or less depending on the user's needs. If the entered BG CF value is outside the acceptable range 176, the user is prompted to reenter an acceptable BG CF value.
  • Once all parameters have been set within proper limits, the fob prompts the user to initiate the SDOS delivery and, in turn, the user initiates the fob to send an SDOS delivery command to the pump [0105] 178. The pump then initiates the SDOS delivery to the user 180.
  • 3. Combined Calculator Mode [0106]
  • Referring now to FIG. 4C, upon selecting the combined carbohydrate/blood glucose calculator mode (CBG CALC) [0107] 190, the user is queried to enter the amount of carbohydrates he or she anticipates eating and the fob determines the XDOS) based on this CARB value and the preprogrammed B/C RATIO, according to the collective steps 192 of FIG. 4A. Then, according to the collective steps 194 of FIG. 4B, the user enters his or her ACTUAL BG and the fob determines the SDOS to be delivered based on the ACTUAL BG and preprogrammed values of the user's B/BG RATIO and TARGET BG. In another embodiment of the invention, the user's ACTUAL BG is automatically transmitted to the fob which then determines the SDOS to be delivered based on the ACTUAL BG and based on preprogrammed values of the user's B/BG RATIO and TARGET BG.
  • The fob then prompts the user to select a correction factor (COMBO CF) (Units) [0108] 196 to adjust the XDOS if necessary, i.e., to either decrease or increase the XDOS to fine-tune the bolus volume, for example, when the user anticipates exercising soon after a meal. The COMBO CF value must be within a range from a minimum value (MIN COMBO CF) to a maximum value (MAX COMBO CF) 198. For an average user, the COMBO CF is typically from about 0 Units to 10 Units, but may be more or less depending on the user's needs. If the entered COMBO CF value is outside the acceptable range, the user is prompted to reenter an acceptable COMBO CF value.
  • Once all parameters have been set within proper limits, the fob prompts the user to initiate the XDOS delivery and, in turn, the user initiates the fob to send an XDOS delivery command to the pump [0109] 200. The pump then initiates the XDOS delivery to the user 202.
  • Methods [0110]
  • As summarized above, the subject invention provides methods for remotely controlling medication infusion to a patient. With reference to FIG. 5, certain methods of the present invention are now described in detail. After the initial programming of the pump and fob of the subject system, typically performed by the user's physician, the fob will typically remain in a sleep mode [0111] 220 until initiated by the user 222. Upon such initiation, the fob, via the communication link, requests the pump to provide the fob with the pump status information, e.g., bolus in progress status, basal in progress, remaining insulin, etc., and algorithm configuration information, e.g., default values including, but not limited to, B/C RATIO, B/BG RATIO, TARGET BG, bolus limits, bolus steps, programming configurations, i.e., extended or dual bolus functions selected, carbohydrate or blood glucose calculator mode selected. Upon receiving this request, the pump transmits the requested status and configuration information to the fob 224, which is then received by the fob 226.
  • If this, information indicates that a bolus delivery is in progress [0112] 228, the fob will display the “Bolus in Progress” menu 230 and query the user as to whether he or she wants to stop the bolus delivery 232. If the user indicates that he or she does wish to stop the bolus delivery, the fob transmits a STOP BOLUS command to the pump 234. Upon receipt of this command, the pump stops the bolus delivery and transmits the revised pump status information to the fob 236. The fob displays this status information to the user 238, and, after a short time, goes back into sleep mode 240.
  • If, on the other hand, the user does not want to stop the bolus in progress [0113] 242 or no bolus is currently in progress 244, the fob displays the pump status information and the “Bolus Function” menu 246. The user then selects the desired bolus program, e.g., standard bolus program, extended bolus program or dual bolus program, and the fob transmits the bolus delivery programming start command to the pump 248. According to this command, the pump resets the bolus delivery timer aid transmits an acknowledgement to the fob 250. The fob then queries the user for specific bolus program data 252, with or without the use of a calculator function, e.g., carbohydrate calculator, blood glucose calculator mode or combined mode, all of which includes entering or selecting all the necessary information requested by the selected algorithms, as illustrated in FIGS. 3A-3C and 4A-4C.
  • Upon (completing the programming of the bolus delivery protocol, the user initiates the fob to transmit the bolus value and DELIVER bolus command to the pump [0114] 254. If the bolus delivery commences prior to expiration of the bolus delivery timer 256, the pump initiates the bolus delivery, cancels the timer and transmits an acknowledgment to the fob 258. After a short time, the fob returns to the sleep mode 260.
  • If, on the other hand, the timer expires prior to commencement of the bolus delivery [0115] 262, the pump initiates an alarm 264, either audio, motion and/or visual as described above to indicate to the user that there is a malfunction with the pump. The pump also initiates an alarm in order to alert the user to preprogrammed reminders, e.g., a reminder to take a blood glucose measurement, etc. Upon being alerted by the alarm, the user initiates the fob from the sleep mode (if asleep), and the fob then requests the pump to provide the fob with the alert/alarm/reminder status 266. The pump, in turn, transmits such information to the fob 268. The fob then displays the alert/alarm/reminder currently in progress upon which the user can initiate the fob to transmit a CANCEL ALARM command to the pump 270 and take care of the cause of the alarm, e.g., unclog the pump infusion tubing, or perform the necessary task, take a blood glucose measurement. In response, the pump cancels the alarm and the bolus delivery timer 272. After a short time, the fob returns to the sleep mode 274.
  • Kits [0116]
  • Also provided by the subject invention are kits for use in practicing the subject methods. The kits of one embodiment of the subject invention include at least one subject infusion pump and at least one subject fob, as described above. The kits may also include one or more pump infusion sets and/or one or more test strips compatible for use with the fob's meter. In another embodiment of the subject invention, the kits include at least one subject measurement device and at least one fob. Other kits include at least one infusion pump, at least one measurement device and at least one fob. The kits may further include software programs recorded on a CD-ROM or the like, which programs may be downloaded to the pump and/or fob by the user or physician by means of an external device, such as a computer. Finally, the kits may further include instructions for using the subject devices. These instructions may be present on one or more of the packaging, label inserts or containers within the kits, or may be provided on a CD-ROM or the like. [0117]
  • It is evident from the above description and discussion that the above-described invention provides a simple, convenient and discrete way of administering a medication protocol to a patient. The present invention minimizes the number of devices that a patient must carry with him or her in order to effectively administer medication and monitor its effects on the patient. The present invention also maximizes the flexibility and real-time control that a patient has over administration of his or her medication. As such, the subject invention represents a significant contribution to the art. [0118]
  • All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. [0119]
  • Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. [0120]

Claims (33)

What is claimed is:
1. A system comprising:
a medication infusion pump configured to be worn on the body of a patient;
a physiological fluid monitoring device configured to be worn on the body of a patient for substantially continuous monitoring of at least one characteristic of physiological fluid; and
a remote control device for remotely controlling the medication infusion pump and the physiological fluid monitoring device, wherein the remote control device comprises a physiological fluid monitoring means for the episodic monitoring of at least one characteristic of physiological fluid.
2. The system of claim 1 wherein said medication infusion pump and physiological monitoring device are integrally housed within a housing configured to be worn on the body of a patient.
3. The system of claim 1 further comprising means for communicating between the remote control device, the medication infusion pump and the physiological fluid monitoring means.
4. The system of claim 3 wherein said means for communicating comprises a first communication module associated with the remote control device and at least a second communication module for transmitting and receiving data to and from the first communication module.
5. The system of claim 1 wherein said remote control device comprises:
a communication module for communicating with the medication infusion pump and with the physiological fluid monitoring device;
one or more control keys for user interface with the remote control device; and
a controller for controlling the transfer and receipt of data to and from the communication module and for processing user interface data.
6. The system of claim 5 wherein said remote control device further comprises memory storage means.
7. The system of claim 5 wherein said remote control device further comprises user interface control keys and a display for displaying user interface data.
8. The system of claim 5 wherein said remote control device further comprises an input/output port for connection to an external device.
9. The system of claim 8 wherein said input/output port further comprises a Universal Serial Bus.
10. The system of claim 1 wherein said remote control device further comprises a port for operatively receiving a physiological fluid test strip.
11. The system of claim 1 wherein said medication infusion pump further comprises a medication reservoir and a drive motor for pumping medication held within said medication reservoir to a site within the patient.
12. The system of claim 1 wherein said medication infusion pump further comprises:
a communication module for communicating with the remote control device;
one or more control keys for user interface with the medication infusion pump; and
a controller for controlling the transfer and receipt of data to and from the remote control device and for processing user interface data.
13. The system of claim 12 wherein said medication infusion pump further comprises memory storage means.
14. The system of claim 12 wherein said medication infusion pump further comprises user interface control keys and a display for displaying user interface data.
15. The system of claim 12 wherein said medication infusion further comprises an input/output port for connection to an external device.
16. The system of claim 11 wherein said medication infusion pump further comprises an alarm means.
17. The system of claim 1 wherein said physiological fluid monitoring device comprises:
a physiological fluid sampling means; and
a sensor for measuring the concentration of one or more analytes within physiological fluid, wherein said sensor is operatively connected and in fluid communication with said physiological fluid sampling means.
18. The system of claim 17 wherein said physiological fluid monitoring device further comprises:
a communication module for communicating with the remote control device;
one or more control keys for user interface with the medication infusion pump; and
a controller for controlling the transfer and receipt of data to and from the remote control device and for processing user interface data.
19. The system of claim 18 wherein said physiological fluid monitoring device further comprises memory storage means.
20. The system of claim 18 wherein said physiological fluid monitoring device further comprises user interface control keys and a display for displaying user interface data.
21. The system of claim 18 wherein said physiological fluid monitoring means further comprises an input/output port for connection to an external device.
22. The system of claim 18 wherein said physiological fluid monitoring means further comprises an alarm means.
23. The system of claim 17 wherein the physiological fluid sampling means comprises a needle.
24. The system of claim 23 wherein the needle has a penetration depth for penetrating into but not through the dermis.
25. The system of claim 27 wherein said physiological fluid sampling means further comprises a pressure sing.
26. A system for administration of medication, comprising:
a medication infusion pump configured to be worn on the body of a patient;
a remote control device for remotely controlling the medication infusion pump; and
a processor associated with said remote control device; and
software for use with said processor for implementing medication delivery protocols by said medication infusion pump, said medication delivery protocols comprising a first medication delivery protocol for the immediate infusion of a selected dosage of medication, a second medication delivery protocol for the infusion of a selected dosage of medication over a selected period of time and a third medication delivery protocol for the immediate infusion of a first selected dosage of medication followed by the infusion of a second selected dosage of medication over a selected period of time.
27. The system of 26 wherein said software comprises algorithms for calculating a patient's current or substantially current blood glucose level or the patient's anticipated or actual carbohydrate intake and for modifying said medication delivery protocols according to said blood glucose level or said carbohydrate intake.
28. A method of monitoring and controlling the concentration of a physiological fluid analyte of patient, comprising:
episodically measuring the concentration of the analyte from a sample of physiological fluid taken from the patient, wherein the episodic measuring is performed using a remote device;
substantially continuously sampling the physiological fluid of the patient using percutaneous means;
substantially continuously measuring the concentration of the analyte within the sampled physiological fluid;
communicating data representative of the analyte concentration to the remote device;
determining whether the analyte concentration falls outside an acceptable range; and
adjusting a medication delivery protocol upon a determination that the analyte concentration falls outside the acceptable range.
29. The method of claim 28 wherein said adjusting is performed automatically in response to said determination.
30. The method of claim 28 wherein said adjusting is initiated by the patient or a physician.
31. The method of claim 28 wherein said communicating comprises transmitting radio frequency signals.
32. A method of monitoring and controlling a patient's glucose level, comprising:
episodically measuring the concentration of glucose from a sample of physiological fluid taken from the patient;
providing a value representative of the patient's carbohydrate intake;
calculating a dosage of insulin to be administered to the patient based on said glucose concentration and based on said carbohydrate intake value;
transmitting a radio frequency signal representative of said dosage to an insulin infusion pump worn by the patient, said infusion pump comprising a radio frequency receiver for receiving said radio frequency signal; and
administering said dosage of insulin to the patient by means of said infusion pump.
33. The method of 32 wherein said episodic measuring, said calculating and said transmitting are performed using a remote device.
US10/370,955 2002-02-26 2003-02-20 Systems and methods for remotely controlling medication infusion and analyte monitoring Abandoned US20030212379A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US36040102P true 2002-02-26 2002-02-26
US10/370,955 US20030212379A1 (en) 2002-02-26 2003-02-20 Systems and methods for remotely controlling medication infusion and analyte monitoring

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/370,955 US20030212379A1 (en) 2002-02-26 2003-02-20 Systems and methods for remotely controlling medication infusion and analyte monitoring

Publications (1)

Publication Number Publication Date
US20030212379A1 true US20030212379A1 (en) 2003-11-13

Family

ID=23417816

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/370,955 Abandoned US20030212379A1 (en) 2002-02-26 2003-02-20 Systems and methods for remotely controlling medication infusion and analyte monitoring

Country Status (15)

Country Link
US (1) US20030212379A1 (en)
EP (1) EP1338295A1 (en)
JP (1) JP2003290345A (en)
KR (1) KR20030070857A (en)
CN (1) CN1449840A (en)
AU (2) AU2003200685A1 (en)
CA (1) CA2420136A1 (en)
IL (1) IL154635A (en)
MX (1) MXPA03001781A (en)
NO (1) NO20030850L (en)
PL (1) PL358897A1 (en)
RU (1) RU2003105304A (en)
SG (1) SG155760A1 (en)
TW (1) TW200307571A (en)
WO (1) WO2003071930A2 (en)

Cited By (347)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030163223A1 (en) * 2002-02-28 2003-08-28 Blomquist Michael L. Programmable insulin pump
US20040039256A1 (en) * 2000-11-30 2004-02-26 Masanao Kawatahara Measuring device with comment input function
US20040235446A1 (en) * 2000-12-21 2004-11-25 Flaherty J. Christopher Medical apparatus remote control and method
US20040249253A1 (en) * 2003-06-06 2004-12-09 Joel Racchini Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
WO2005037095A1 (en) * 2003-10-14 2005-04-28 Pelikan Technologies, Inc. Method and apparatus for a variable user interface
US20060001538A1 (en) * 2004-06-30 2006-01-05 Ulrich Kraft Methods of monitoring the concentration of an analyte
US20060010098A1 (en) * 2004-06-04 2006-01-12 Goodnow Timothy T Diabetes care host-client architecture and data management system
WO2006032653A2 (en) * 2004-09-23 2006-03-30 Novo Nordisk A/S Device for self-care support
US20060116554A1 (en) * 2002-07-12 2006-06-01 Gerrat Dijkman Universal measuring device for medical application
US20060211981A1 (en) * 2004-12-27 2006-09-21 Integrated Sensing Systems, Inc. Medical treatment procedure and system in which bidirectional fluid flow is sensed
US20060226985A1 (en) * 2005-02-08 2006-10-12 Goodnow Timothy T RF tag on test strips, test strip vials and boxes
US20060276771A1 (en) * 2005-06-06 2006-12-07 Galley Paul J System and method providing for user intervention in a diabetes control arrangement
WO2007005219A1 (en) * 2005-06-29 2007-01-11 Medtronic Minimed, Inc. Infusion device with bolus alarm deactivation and method of using the same
US20070040449A1 (en) * 2005-08-16 2007-02-22 Medtronic Monimed, Inc. Method and apparatus for predicting end of battery life
US20070066940A1 (en) * 2005-09-19 2007-03-22 Lifescan, Inc. Systems and Methods for Detecting a Partition Position in an Infusion Pump
US20070062250A1 (en) * 2005-09-19 2007-03-22 Lifescan, Inc. Malfunction Detection With Derivative Calculation
WO2007035658A2 (en) * 2005-09-19 2007-03-29 Lifescan, Inc. Infusion pumps with a position detector
US20070083088A1 (en) * 2003-09-12 2007-04-12 Laborie Medical Technologies Inc. Apparatus and method for medical measurement
US20070112298A1 (en) * 2005-11-17 2007-05-17 Medtronic Minimed, Inc. External infusion device with programmable capabilities to time-shift basal insulin and method of using the same
US20070185460A1 (en) * 2003-08-28 2007-08-09 Lionel Vedrine Intradermal injection device
WO2007101260A2 (en) * 2006-02-28 2007-09-07 Abbott Diabetes Care, Inc. Smart messages and alerts for an infusion delivery and management system
US20070233206A1 (en) * 2006-03-29 2007-10-04 Disetronic Licensing Ag Method and arrangement for monitoring a medical appliance
EP1849405A1 (en) 2006-04-28 2007-10-31 Sysmex Corporation Measuring method and measuring device for extraction and measurement of interstitial fluid
US20080033402A1 (en) * 2006-08-03 2008-02-07 Blomquist Michael L Interface for medical infusion pump
US20080071580A1 (en) * 2005-06-03 2008-03-20 Marcus Alan O System and method for medical evaluation and monitoring
WO2008038274A1 (en) * 2006-09-29 2008-04-03 Medingo Ltd. Fluid delivery system with electrochemical sensing of analyte concentration levels
US20080114299A1 (en) * 2004-09-23 2008-05-15 Camilla Damgaard-Sorensen Remote Commander To Be Used With A Drug Delivery Device
US20080124692A1 (en) * 2006-10-26 2008-05-29 Mcevoy Mary Method for tutoring a user during use of a system for determining an analyte in a bodily fluid sample
US20080154187A1 (en) * 2006-12-21 2008-06-26 Lifescan, Inc. Malfunction detection in infusion pumps
US20080214919A1 (en) * 2006-12-26 2008-09-04 Lifescan, Inc. System and method for implementation of glycemic control protocols
US20080213308A1 (en) * 2004-09-14 2008-09-04 Nicholas Valiante Imidazoquinoline Compounds
US20080228048A1 (en) * 2007-03-12 2008-09-18 Honeywell International, Inc. Physiological Sensors with Telemonitor and Notification Systems
US20080287922A1 (en) * 2005-06-27 2008-11-20 Novo Nordisk A/S User Interface for Delivery System Providing Graphical Programming of Profile
US20090005728A1 (en) * 2007-06-27 2009-01-01 Roche Diagnostics Operations, Inc. Therapy delivery system having an open architecture and a method thereof
US20090018495A1 (en) * 2005-06-27 2009-01-15 Novo Nordisk A/S User Interface For Delivery System Providing Shortcut Navigation
WO2009015497A1 (en) * 2007-06-28 2009-02-05 F. Hoffmann-La Roche Ag Combination of infusion pump and measuring device
US20090069714A1 (en) * 2007-09-11 2009-03-12 Ashlar Holdings, Llc System and method for measuring data for medical applications
US20090095292A1 (en) * 2006-04-10 2009-04-16 Canon Kabushiki Kaisha Ingesta administration device
US20090099506A1 (en) * 2002-07-24 2009-04-16 Medtronic Minimed, Inc. System for Providing Blood Glucose Measurements to an Infusion Device
US20090118592A1 (en) * 2005-12-08 2009-05-07 Novo Nordisk A/S Medical System Comprising a Sensor Device
US20090209904A1 (en) * 2004-01-27 2009-08-20 Peeters John P Diagnostic Radio Frequency Identification Sensors And Applications Thereof
US20090212966A1 (en) * 2005-06-27 2009-08-27 Novo Nordisk A/S User Interface for Delivery System Providing Dual Setting of Parameters
US20090232844A1 (en) * 2006-03-23 2009-09-17 James Sutton Immunopotentiating compounds
US20090264720A1 (en) * 2008-04-17 2009-10-22 The Cooper Health System Wearable Automated Blood Sampling and Monitoring System
US20090318791A1 (en) * 2006-06-30 2009-12-24 Novo Nordisk A/S Perfusion Device with Compensation of Medical Infusion During Wear-Time
US20090326509A1 (en) * 2008-06-30 2009-12-31 Muse Philip A Context aware medical monitoring and dosage delivery device
US20090326445A1 (en) * 2006-10-04 2009-12-31 Henning Graskov User Interface for Delivery System Comprising Diary Function
US20100017141A1 (en) * 2008-07-18 2010-01-21 Insulet Corporation Calculating insulin on board for extended bolus being delivered by an insulin delivery device
US20100016700A1 (en) * 2008-07-18 2010-01-21 Lifescan, Inc. Analyte measurement and management device and associated methods
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US20100049119A1 (en) * 2008-08-22 2010-02-25 Norman Gerould W Surgical fluid management system
USD611151S1 (en) 2008-06-10 2010-03-02 Lifescan Scotland, Ltd. Test meter
USD611372S1 (en) 2008-09-19 2010-03-09 Lifescan Scotland Limited Analyte test meter
USD611489S1 (en) 2008-07-25 2010-03-09 Lifescan, Inc. User interface display for a glucose meter
US7679407B2 (en) 2003-04-28 2010-03-16 Abbott Diabetes Care Inc. Method and apparatus for providing peak detection circuitry for data communication systems
USD611853S1 (en) 2008-03-21 2010-03-16 Lifescan Scotland Limited Analyte test meter
US20100069890A1 (en) * 2006-12-14 2010-03-18 Novo Nordisk A/S User interface for medical system comprising diary function with time change feature
USD612279S1 (en) 2008-01-18 2010-03-23 Lifescan Scotland Limited User interface in an analyte meter
USD612275S1 (en) 2008-03-21 2010-03-23 Lifescan Scotland, Ltd. Analyte test meter
US7697967B2 (en) 2005-12-28 2010-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US20100095229A1 (en) * 2008-09-18 2010-04-15 Abbott Diabetes Care, Inc. Graphical user interface for glucose monitoring system
USD615431S1 (en) 2008-03-21 2010-05-11 Lifescan Scotland Limited Analyte test meter
US20100125241A1 (en) * 2008-11-17 2010-05-20 Disetronic Licensing, Ag Prandial Blood Glucose Excursion Optimization Method Via Computation of Time-Varying Optimal Insulin Profiles and System Thereof
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US20100141391A1 (en) * 2006-09-29 2010-06-10 Nellcor Puritan Bennett Llc User interface and identification in a medical device system and method
US7736310B2 (en) 2006-01-30 2010-06-15 Abbott Diabetes Care Inc. On-body medical device securement
US20100152548A1 (en) * 2006-11-20 2010-06-17 Salla Koski Measurement device, system and method
US20100160860A1 (en) * 2007-06-29 2010-06-24 Celentano Michael J Apparatus and method for remotely controlling an ambulatory medical device
US20100161240A1 (en) * 2008-12-24 2010-06-24 Chao-Man Tseng Test strip and device for measuring sample properties and system incorporating the same
US20100160740A1 (en) * 2008-12-24 2010-06-24 Gary Cohen Use of Patterns in a Therapy Management System
US20100161236A1 (en) * 2008-12-24 2010-06-24 Gary Cohen Pattern Recognition and Filtering in a Therapy Management System
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US7768387B2 (en) 2007-04-14 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US7768386B2 (en) 2007-07-31 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7768408B2 (en) 2005-05-17 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US7801582B2 (en) 2006-03-31 2010-09-21 Abbott Diabetes Care Inc. Analyte monitoring and management system and methods therefor
US20100240079A1 (en) * 2007-08-23 2010-09-23 James Jackson Glucose tolerace test device
AU2005202516B2 (en) * 2004-06-30 2010-09-23 Lifescan Scotland Limited Fluid handling devices
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US7822455B2 (en) 2006-02-28 2010-10-26 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US7826382B2 (en) 2008-05-30 2010-11-02 Abbott Diabetes Care Inc. Close proximity communication device and methods
US20100286601A1 (en) * 2007-12-26 2010-11-11 Ofer Yodfat Maintaining glycemic control during exercise
US20100324382A1 (en) * 2009-06-17 2010-12-23 Medtronic Minimed, Inc. Closed-loop glucose and/or insulin control system
US7860544B2 (en) 1998-04-30 2010-12-28 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20100331650A1 (en) * 2009-06-25 2010-12-30 Roche Diagnostics Operations, Inc. Episodic blood glucose monitoring system with an interactive graphical user interface and methods thereof
US7875047B2 (en) 2002-04-19 2011-01-25 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7901365B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US20110060202A1 (en) * 2009-09-08 2011-03-10 Seth Adrian Miller Dehydration detector using micro-needles
US7909777B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7909775B2 (en) 2001-06-12 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7909774B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7914465B2 (en) 2002-04-19 2011-03-29 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US7922458B2 (en) 2002-10-09 2011-04-12 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US20110152769A1 (en) * 2009-12-23 2011-06-23 Roche Diagnostics Operations, Inc. Methods and systems for adjusting an insulin delivery profile of an insulin pump
US20110163881A1 (en) * 2010-01-07 2011-07-07 Lisa Halff System and method responsive to an event detected at a glucose monitoring device
US20110163880A1 (en) * 2010-01-07 2011-07-07 Lisa Halff System and method responsive to an alarm event detected at an insulin delivery device
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7976778B2 (en) 2001-04-02 2011-07-12 Abbott Diabetes Care Inc. Blood glucose tracking apparatus
US7981055B2 (en) 2001-06-12 2011-07-19 Pelikan Technologies, Inc. Tissue penetration device
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US7988645B2 (en) 2001-06-12 2011-08-02 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US7996158B2 (en) 2007-05-14 2011-08-09 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8007446B2 (en) 2002-04-19 2011-08-30 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8016789B2 (en) 2008-10-10 2011-09-13 Deka Products Limited Partnership Pump assembly with a removable cover assembly
US8029441B2 (en) 2006-02-28 2011-10-04 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US8029460B2 (en) 2005-03-21 2011-10-04 Abbott Diabetes Care Inc. Method and system for providing integrated medication infusion and analyte monitoring system
US8034026B2 (en) 2001-05-18 2011-10-11 Deka Products Limited Partnership Infusion pump assembly
US8047811B2 (en) 2002-10-09 2011-11-01 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US8062231B2 (en) 2002-04-19 2011-11-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8066672B2 (en) 2008-10-10 2011-11-29 Deka Products Limited Partnership Infusion pump assembly with a backup power supply
US8079960B2 (en) 2002-04-19 2011-12-20 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US8085151B2 (en) 2007-06-28 2011-12-27 Abbott Diabetes Care Inc. Signal converting cradle for medical condition monitoring and management system
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8112138B2 (en) 2005-06-03 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US8116840B2 (en) 2003-10-31 2012-02-14 Abbott Diabetes Care Inc. Method of calibrating of an analyte-measurement device, and associated methods, devices and systems
US8113244B2 (en) 2006-02-09 2012-02-14 Deka Products Limited Partnership Adhesive and peripheral systems and methods for medical devices
US8121857B2 (en) 2007-02-15 2012-02-21 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8127046B2 (en) 2006-12-04 2012-02-28 Deka Products Limited Partnership Medical device including a capacitive slider assembly that provides output signals wirelessly to one or more remote medical systems components
US8133197B2 (en) 2008-05-02 2012-03-13 Smiths Medical Asd, Inc. Display for pump
US8135548B2 (en) 2006-10-26 2012-03-13 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US8140142B2 (en) 2007-04-14 2012-03-20 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US8149117B2 (en) 2007-05-08 2012-04-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8160900B2 (en) 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US20120101474A1 (en) * 2005-09-13 2012-04-26 Medtronic Minimed, Inc. Modular external infusion device
US8185181B2 (en) 2009-10-30 2012-05-22 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US8197421B2 (en) 2002-04-19 2012-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8208984B2 (en) 2007-01-24 2012-06-26 Smiths Medical Asd, Inc. Correction factor testing using frequent blood glucose input
US8206296B2 (en) 2006-08-07 2012-06-26 Abbott Diabetes Care Inc. Method and system for providing integrated analyte monitoring and infusion system therapy management
US8211016B2 (en) 2006-10-25 2012-07-03 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8223028B2 (en) 2008-10-10 2012-07-17 Deka Products Limited Partnership Occlusion detection system and method
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8250483B2 (en) * 2002-02-28 2012-08-21 Smiths Medical Asd, Inc. Programmable medical infusion pump displaying a banner
US8252229B2 (en) 2008-04-10 2012-08-28 Abbott Diabetes Care Inc. Method and system for sterilizing an analyte sensor
US8251921B2 (en) 2003-06-06 2012-08-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US8251904B2 (en) 2005-06-09 2012-08-28 Roche Diagnostics Operations, Inc. Device and method for insulin dosing
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8262614B2 (en) 2003-05-30 2012-09-11 Pelikan Technologies, Inc. Method and apparatus for fluid injection
US8262616B2 (en) 2008-10-10 2012-09-11 Deka Products Limited Partnership Infusion pump assembly
US8267892B2 (en) 2008-10-10 2012-09-18 Deka Products Limited Partnership Multi-language / multi-processor infusion pump assembly
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US20120245522A1 (en) * 2005-11-08 2012-09-27 Asante Solutions, Inc. Method and System for Manual and Autonomous Control of an Infusion Pump
US20120249294A1 (en) * 2011-03-29 2012-10-04 O'connor Sean Biometric pairing for insulin infusion system
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US8287454B2 (en) 1998-04-30 2012-10-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20120265722A1 (en) * 2007-05-24 2012-10-18 Michael Blomquist Expert system for insulin pump therapy
US8296918B2 (en) 2003-12-31 2012-10-30 Sanofi-Aventis Deutschland Gmbh Method of manufacturing a fluid sampling device with improved analyte detecting member configuration
US8333710B2 (en) 2002-04-19 2012-12-18 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8333714B2 (en) 2006-09-10 2012-12-18 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8344966B2 (en) 2006-01-31 2013-01-01 Abbott Diabetes Care Inc. Method and system for providing a fault tolerant display unit in an electronic device
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8343093B2 (en) 2002-10-09 2013-01-01 Abbott Diabetes Care Inc. Fluid delivery device with autocalibration
US8353881B2 (en) 2005-12-28 2013-01-15 Abbott Diabetes Care Inc. Infusion sets for the delivery of a therapeutic substance to a patient
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8368556B2 (en) 2009-04-29 2013-02-05 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US8372016B2 (en) 2002-04-19 2013-02-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US8382682B2 (en) 2002-04-19 2013-02-26 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US20130079709A1 (en) * 2008-07-01 2013-03-28 Roche Diagnostics International Ag Insulin pump and method for controlling a user interface of an insulin pump
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8414563B2 (en) 2007-12-31 2013-04-09 Deka Products Limited Partnership Pump assembly with switch
US8435206B2 (en) 2006-08-03 2013-05-07 Smiths Medical Asd, Inc. Interface for medical infusion pump
US8435190B2 (en) 2002-04-19 2013-05-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8439872B2 (en) 1998-03-30 2013-05-14 Sanofi-Aventis Deutschland Gmbh Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8460243B2 (en) * 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US8467972B2 (en) 2009-04-28 2013-06-18 Abbott Diabetes Care Inc. Closed loop blood glucose control algorithm analysis
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US8483967B2 (en) 2009-04-29 2013-07-09 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US8504179B2 (en) 2002-02-28 2013-08-06 Smiths Medical Asd, Inc. Programmable medical infusion pump
US8515517B2 (en) 2006-10-02 2013-08-20 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US8514086B2 (en) 2009-08-31 2013-08-20 Abbott Diabetes Care Inc. Displays for a medical device
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US8512244B2 (en) 2006-06-30 2013-08-20 Abbott Diabetes Care Inc. Integrated analyte sensor and infusion device and methods therefor
US8545403B2 (en) 2005-12-28 2013-10-01 Abbott Diabetes Care Inc. Medical device insertion
US8556829B2 (en) 2002-04-19 2013-10-15 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8560082B2 (en) 2009-01-30 2013-10-15 Abbott Diabetes Care Inc. Computerized determination of insulin pump therapy parameters using real time and retrospective data processing
US8571624B2 (en) 2004-12-29 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for mounting a data transmission device in a communication system
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US8583205B2 (en) 2008-03-28 2013-11-12 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8579853B2 (en) 2006-10-31 2013-11-12 Abbott Diabetes Care Inc. Infusion devices and methods
US20130303980A1 (en) * 2002-07-24 2013-11-14 Medtronic Minimed, Inc. System for Providing Blood Glucose Measurements to an Infusion Device
US8593109B2 (en) 2006-03-31 2013-11-26 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8591410B2 (en) 2008-05-30 2013-11-26 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8597188B2 (en) 2007-06-21 2013-12-03 Abbott Diabetes Care Inc. Health management devices and methods
US8612159B2 (en) 1998-04-30 2013-12-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8613892B2 (en) 2009-06-30 2013-12-24 Abbott Diabetes Care Inc. Analyte meter with a moveable head and methods of using the same
US8613703B2 (en) 2007-05-31 2013-12-24 Abbott Diabetes Care Inc. Insertion devices and methods
US8617069B2 (en) * 2007-06-21 2013-12-31 Abbott Diabetes Care Inc. Health monitor
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US20140025809A1 (en) * 2012-07-19 2014-01-23 Cepheid Remote monitoring of medical devices
US8638220B2 (en) 2005-10-31 2014-01-28 Abbott Diabetes Care Inc. Method and apparatus for providing data communication in data monitoring and management systems
US8641618B2 (en) 2007-06-27 2014-02-04 Abbott Diabetes Care Inc. Method and structure for securing a monitoring device element
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US8652043B2 (en) 2001-01-02 2014-02-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8663201B2 (en) 2005-08-16 2014-03-04 Medtronic Minimed, Inc. Infusion device
US8668656B2 (en) 2003-12-31 2014-03-11 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8708376B2 (en) 2008-10-10 2014-04-29 Deka Products Limited Partnership Medium connector
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US8721671B2 (en) 2001-06-12 2014-05-13 Sanofi-Aventis Deutschland Gmbh Electric lancet actuator
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US8764657B2 (en) 2010-03-24 2014-07-01 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8771251B2 (en) 2009-12-17 2014-07-08 Hospira, Inc. Systems and methods for managing and delivering patient therapy through electronic drug delivery systems
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US8795252B2 (en) 2008-08-31 2014-08-05 Abbott Diabetes Care Inc. Robust closed loop control and methods
US8798934B2 (en) 2009-07-23 2014-08-05 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
US20140222447A1 (en) * 2005-05-09 2014-08-07 Theranos, Inc. Systems and methods for improving medical treatments
US8828203B2 (